Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 484-488

  Miremadi, Saman ^a   Sniderman, Allan ^a   Frohlich, Jiri ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; DYSLIPIDEMIA; FOLLOW UP; HEMOCONCENTRATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRACTICE GUIDELINE; RISK ASSESSMENT; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 0036177348     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.3.484     Document Type: Article

References (27)

1. Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and other Dyslipidemias
2. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B
3. Composition and distribution of low-density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia and familial hypercholesterolemia
4. A prospective study of triglyceride level, low density lipoprotein particle diameter and risk of myocardial infarction
5. LDL size and risk of coronary heart disease in elderly men and women
6. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five year follow up of men in the Quebec cardiovascular study
7. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
8. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas Atherosclerosis Regression Study (STARS)
9. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
10. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
11. Thrombogenic factors and recurrent coronary events
12. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
13. Apolipoprotein concentrations during treatment and recurrent coronary artery events
14. Prediction of coronary heart disease using risk factor categories
15. Reference values of plasma apolipoproteins A-1 and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan
16. Lipids and Cardiovascular disease
17. Serum and lipoprotein apolipoprotein B levels in normal subjects and patient with hyperlipoproteinemia
18. Myocardial infarction in the familial forms of hypertriglyceridemia
19. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis
20. Clinical significance of measurements of apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease
21. Serum apolipoproteins A1 and B and lipoproteins in middle-aged men with and without previous myocardial infarction
22. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease
23. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease
24. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec cardiovascular study)
25. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material
26. Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus
27. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?